Study S000789

Comparative Pharmacokinetics of Dulaglutide After Administration Via an Auto-injector and a Manual Syringe in Healthy Subjects

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT01524770
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: COMPLETED
Enrollment: 50
Start: 2012-03
Primary completion: 2012-06
Lead sponsor: Eli Lilly and Company
Conditions: Diabetes Mellitus, Type 2
Interventions: BIOLOGICAL:Dulaglutide
Results posted: TRUE
Secondary identifiers: OTHER:H9X-MC-GBDT

Registered primary outcomes

Pharmacokinetics: Area Under the Concentration Curve (AUC[0-336]) for Dulaglutide [Predose to 336 hours postdose]
Pharmacokinetics: Maximum Concentration (Cmax) for Dulaglutide [Predose to 336 hours postdose]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.